Arfolitixorin - a drug candidate
for treatment of colorectal cancer

More than 370 000 CRC patients
could be treated
with arfolitixorin

The global Phase III clinical study - AGENT

The AGENT study with arfolitixorin

is ongoing at more than 70 hospitals

in The US, Canada and Europe

See how arfolitixorin
works in cancer cells

See the animation

Previous

Next

Startpage 2

Press releases & Latest news

Patent approved in Japan for Isofol’s drug candidate arfolitixorin

Patent approved in Japan for Isofol’s drug candidate arfolitixorin

December 20, 2019 by

GOTHENBURG, Sweden, December 20, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL). A patent covering the Active…

Patent detecting how patients respond to folate-based cancer treatment approved in the USA

Patent detecting how patients respond to folate-based cancer treatment approved in the USA

December 13, 2019 by Admin Isofol

GOTHENBURG, Sweden, December 13, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announces the approval from…

Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

Isofol to Expand Global Phase 3 AGENT Trial in First-Line Metastatic Colorectal Cancer to Australia

November 18, 2019 by

GOTHENBURG, Sweden, November 18, 2019 – Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced the successful completion…

Upcoming Events

January 23, 2020 - January 25, 2020
ASCO Gastrointestinal Cancers Symposium, San Francisco, USA >>
Isofol will attend at a Symposium during this event.
March 03, 2020 - March 04, 2020
Carnegie Nordic Healthcare Seminar
Isofol presenterar at the Carnegie Nordic Healthcare Seminar in Stockholm.

©2019 Isofol Medical AB (publ) Biotech Center, Arvid Wallgrens Backe 20, SE-413 46 Gothenburg, Sweden.

Isofol´s Glossary

Isofol's website uses cookies to improve and customize your visit. By continuing you accept this.Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.

Necessary Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.